 Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that a research paper describing the mechanism of action for the Companys first second-generation Bicycle Toxin Conjugate BTC, BT5528, has been published in the American Association for Cancer Research AACR journal Molecular Cancer Therapeutics. The manuscript, titled MMAE delivery using the Bicycle toxin conjugate BT5528, discusses the preclinical profile of BT5528, which has physiochemical properties thought to enable more favorable safety and efficacy profiles than antibody drug conjugates ADCs with the same tumor antigen target and similar cytotoxic payload. The e-publication can be found here. 